Litcius/Paper detail

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial

Éric Pujade-Lauraine, Jessica Brown, Alan Barnicle, Philip Rowe, Pierre Lao‐Sirieix, Steven W. Criscione, Andreas du Bois, Domenica Lorusso, Ignacio Romero, Edgar Petru, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Magali Provansal, Barbara Schmalfeldt, Sandro Pignata, Cristina Martín-Lorente, Dominique Berton, Ingo B. Runnebaum, Isabelle Ray‐Coquard

2021Gynecologic Oncology23 citationsDOI

Topics & Concepts

OlaparibMedicineBevacizumabOvarian cancerOncologyInternal medicinePARP inhibitorMaintenance therapyHazard ratioBRCA mutationHomologous recombinationProgression-free survivalCancerChemotherapyConfidence intervalGeneGeneticsBiologyPoly ADP ribose polymerasePolymerasePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial | Litcius